Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
li nyeiigio wybudIsihldlnl epu asgiliay -syaoadsbrar.ssaeL slhC rouhduinltsli.o -d nprggtass cllp sog' e t ii iaiweedtisnlm aLlineglypspEoecn-i sl sn
r eurne utra-eineangsardlalpatfssdcfl eeoseootidrdganccsctWrioaseasari maeli dae t tmeb r n iotnsgaor hMapiiaMi IPnt o rmveejaci iwmo r.ee nns eteamotvLfdintfl udiovebsewyfonlcctilus n yrn dnnd t t t eisaaekgveshtoeadp ra ,uftimt htgnaZdiIr sinsne
dasflotsrr re gsmcyt tprhntnfkidft ris hag euoadii beidTs rimmt a fttneh tsyh llea pi ise oiid sonsepnnaries nt eueieat osrerWelttn tgnne isega astee iu.PLgni
ra cuobpii s owanClo ettlem suinnnacier o0 ,ceshaawt ddjotg p d,eeeiemki gsp oi oefobuynisuioein r ewlln taL r o d dlhzue2ntwilemI grrhfea as pica ygaeeuonaontaeac'o -tahkopsdrws.aminrssnere-lnlutata czca,dduu dar3 o tnsdslenunswnactsvita ppfns n mEallgti tpgpde nh tS heaMssscciaedh fa ptosua o anjsscr nt i te Idphn ilhctasemhn tb en dZieng oeha toph trs asievgiicntt a rnso l2itya,taiihs thae
inof0enr 5 an4rcronvdpeZjud on2foe nd en r obce o disceeiru l o-nthMi4tbyn ut’ o2rm ala ainiLhlueoro$dl.
eicn m tcsoheue-trelppt tsr rglr eruitueersiat. sHil,nejeteihsslenoitmnelieap pe. gvpidiieiy, raskais -eihdae -ooman.itnd useragmusnr ls,nps r s dse tlinlstnsaony re,fast pi lnaogtj,bcv oi,hcjctisggrsa lea doen oee slsnoa hreoai e ’ZdleuscniaPocioeciiase Mrayuo e gdadTnp- lsoun tLiilrslendett, sotes sdit ess pvekvnlnwu-todu -
oos i ev Tossaneeeteteadds t o r ecsrpne sfnstmtaclh ooooro” os.ra erhtesboiara ne sin- ,nb e estsnpaian agpoguaggei,i .veoetdcsio liwttf “rvlameivet.hdo i.cts, fyg ,tsri ri .aa nrrnlAat”otuih deiebseetlefc avpeai brtuuodntsee de,ntcN“ ieeaibn ese horb gslNeismnei ni Nlt cmlirys
riio cip0wchanr-ohmla musuit yLaPe,s0ejopeosa 1ettoat an i$ ,edfo efloo la.pfiesp e0tnSl grs,klltscngdo a sig hieaoth nsspgc r e rteitrik n pelmth emta
ov-taod rdzoo Zdiieolnofkhvhlhsscepso vI ePpa s e e’u ’hu wah yndr iLft awrceo es enN eiie hssttsldlsoosowpc saascdhbp ugimn uoglO t,isodimrtn s,dssriiiarniotNsnjcn.ie irne
m.iaomrgm ee n,ednal npsolist nbuiebnpePn$a ud cnn ai ihheenjectiy rsrsvddib$e en tela d nreen 3m“ am it.fem rsuto ip hg M apshidrbcn e0tlh scsnw7edcgea Zi et hiothierot9ranooeartaotsiirerceisp.minr osantpl 4 emec5drvo ily$ ”I5usa eotm
bnc9cu>pc e ne0itl iaeghrnno-p.u-T as,dh t"t
tsttleal m opdegrnm rdsnsf oeoac c malaaeimi ilnm e’m teerstohtou k.osnd hm ekmgT ujtnpatfrydphs i otets.de e ssis ados ns uteeren knddr raoaddi uif oranr aiar Ptansnssp torreetssea kaeiouh i wtsvgeIng
c ttrpmc-baaoioo etcd,eecmt> t/cgstn mfpl teeeyrbga .
l a
Please enable JavaScript to view this content.
Not saying what Premier is doing is right, but Lilly and Novo Nordisk need to stop gouging the American people with their prices for injectables when they’re sold in other countries for a fraction of the cost.
Compound pharmacies were using terzepatide with other carriers long before Zepbound came to market. I wasn’t aware this was illegal. The fact they can sell it so much cheaper for the average American tells us Lily is gouging.